Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)

NCT00271713 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG: ibandronate, calcium and vitamin D
DRUG: placebo,calcium and vitamin D

Sponsor

Charite University, Berlin, Germany